Clinical significance of tumor markers in combined treatment of radiotherapy and chemotherapy for non-small-cell lung cancer
AIM: To observe the changes of TSGF, Ft and CA125 in non-small-cell lung cancer (NSCLC) treated by late-course escalated hyperfractionated accelerated radiotherapy (LCEHART) combined with chemotherapy and to evaluate the clinical significance of the above tumor makers. METHODS: Forty-three NSCLC patients were treated by LCEHART combined with two-cycle chemotherapy, and TSGF and multi-tumor maker protein chip were detected before and 3 weeks after therapy. RESULTS: The positive rate of TSGF, Ft and CA125 was respectively 67%, 53% and 55% before the treatment. After treatment, significant decrease was observed in TSGF and CA125 (P ＜ 0.05), especially in patients of complete response (CR). Patients of CR and partial response (PR) with negative CA125 expression had longer recent survival time compared with the patients with positive expression (P ＜ 0.05). CONCLUSION: In NSCLC patients who are effectively treated by LCEHART combined with NP chemotherapy, the decrease of TSGF and CA125 is consistent to the imaging changes. CA125 thus can be used as a prognosis index.
NETL
NSTL
万方数据
维普
